Trial · NCT07881562
Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial.
NCT07881562, Phase 4, Not yet recruiting, Region Skane
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial. Trials, record NCT07881562. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881562
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Perioperative Esketamine Safety and Efficacy in Reducing Postoperative ENDometriosis PAIN (the ENDPAIN Trial): a Randomized Controlled Trial.
- NCT number
- NCT07881562
- Status
- Not yet recruiting
- Phases
- Phase 4
- Enrollment
- 1,000 participants, estimated
- Lead sponsor
- Region Skane
- Conditions
- Endometriosis
- Interventions
- Esketamine, Placebo
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time weighted longitudinal postoperative pain measurement over 48 hours. | From 30 minutes after awakening till 48 hours postoperative | A time-weighted longitudinal postoperative pain measurement over 48 hours, measured using the numeric rating scale (NRS, 0-10) for pain at 30 minutes after admission to the PACU, 6, 12, 24 and 48 hours postoperatively during activity (coughing or sitting) |
| Secondary | Hospital-free days within 30 days after surgery | From surgery day until 30 day postoperative | Days spent outside of the hospital during the first 30 postoperative days |
| Secondary | Opioid consumption in the PACU and at 6, 12, 24 and 48 hours after surgery | From awakening until 48 hours postoperative | Opioid consumption in the PACU and at 6, 12, 24 and 48 hours after surgery, measured as a sum of all opioids - intravenously and orally -converted to Oral Morphine Equivalents (OME; mg), administered in the PACU, in the ward, or at home after discharge if this happens before 48 hours after surgery |
| Secondary | Quality of recovery-15 questionnaire (QoR-15) at 24 hours postoperatively | At 24 hours after surgery | Quality of recovery-15 questionnaire (QoR-15) at 24 hours postoperatively |
| Secondary | The proportion of participants with one or more serious adverse events within 48 hours | From drug administration until 48 hours after surgery | The proportion of participants with one or more serious adverse events (defined according to the International Council for Harmonization good clinical practice guidelines) within 48 hours |
| Secondary | The proportion of participants with one or more selected treatment-emergent adverse events within 48 hours postoperatively | From drug administration until 48 hours after surgery | The proportion of participants with one of the following treatment-emergent adverse events within 48 hours postoperatively: * Tachycardia, defined as a heart rate \> 120 bpm for more than 15 minutes; * Hypertension, defined as a systolic blood pressure \> 180 mmHg and/or a diastolic blood pressure \> 100 mmHg for more than 15 minutes; * Sedation, defined as a RASS scale score \< -1 * Dissociation/hallucination/dizziness, defined as any reported episode of dissociation or hallucination; * Nausea/vomiting, defined as the administration of any additional antiemetic drug requested by the participant or as any reported episode of nausea and/or vomiting; |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881562
GET https://conductscience.org/api/trials/v1/NCT07881562/registered